Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance

Citius Pharmaceuticals IncTrade
iShares 1 3 Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while iShares 1 3 Year Treasury Bond ETF trades at $81.95. Which is the better fit depends on your goals.

CTXRSHY
Market Cap
$20.01M
Sector
HealthFixed Income
52-Week High
$1.82$83.18
52-Week Low
$0.48$81.77
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

iShares 1 3 Year Treasury Bond ETF

SHY, the iShares 1-3 Year Treasury Bond ETF, trades at $81.955, up 0.12% on the day, with a bearish technical signal driven by moving averages. Recent news highlights institutional accumulation, including Barry Investment Advisors increasing its stake by 48.1% in Q2 2026 (SEC filing, August 10, 2026), amid fluctuating Treasury yields influenced by inflation data and Middle East tensions. The ETF maintains a steady dividend schedule, with recent payouts of $0.24-$0.25 per share.

Outlook remains cautious due to interest rate uncertainty and inflation pressures, offering income stability but limited growth. Risks include Fed policy shifts and oil-price volatility, while institutional buying signals defensive positioning. The neutral oscillator reading suggests short-term consolidation near current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About iShares 1 3 Year Treasury Bond ETF

SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.

Read more on SHY